Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial

Metabolism: Clinical and Experimental

Volumn 57, Issue 1, 2008, Pages 77-83

  Asztalos, Bela F ^a   Collins, Dorothea ^b   Horvath, Katalin V ^a   Bloomfield, Hanna E ^c   Robins, Sander J ^d   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; STROKE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; GEMFIBROZIL; HUMANS; HYPERTENSION; LIPIDS; LIPOPROTEINS, HDL; MALE; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 36849023953     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.08.009     Document Type: Article

References (29)

1. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
2. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., et al., for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
3. Mowri H.O., Patsch W., Smith L.C., Gotto A.M., and Patsch J.R. Different reactivities of high-density lipoprotein2 subfractions with hepatic lipase. J Lipid Res 33 (1992) 1269-1279
4. Castro G.R., and Fielding C.J. Early incorporation of cell-derived cholesterol into preβ-migrating high density lipoprotein. Biochemistry 27 (1988) 25-29
5. Miida T., Kawano M., Fielding P.E., and Fielding C.J. Regulation of the concentration of preβ high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity. Biochemistry 31 (1992) 11112-11117
6. von Eckardstein A., Huang Y., and Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 5 (1994) 404-416
7. Asztalos B.F., Roheim P.S., Milani R.L., Lefevre M., McNamara J.R., Horvath K.V., et al. Distribution of apo A-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2670-2676
8. Asztalos B.F., Cupples L.A., Demissie S., Horvath K.V., Cox C.E., Batista M.C., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24 (2004) 2181-2187
9. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.E., et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
10. Rubins H.B., Robins S.J., Iwane M.K., Boden W.E., Elam M.B., Fye C.L., et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 71 (1993) 45-52
11. Asztalos B.F., Sloop C.H., Wong L., and Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1169 (1993) 291-300
12. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
13. Robins S.J., and Bloomfield H.E. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 17 (2006) 431-439
14. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
15. Asztalos B.F., de la Llera-Moya M., Dallal G.E., Horvath K.V., Schaefer E.J., and Rothblat G.H. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46 (2005) 2246-2253
16. Brinton E.A., Eisenberg S., and Breslow J.L. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb (1994) 707-720
17. Miida T., Nakamura Y., Inano K., Matsuto T., Yamaguchi T., Tsuda T., et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem 42 (1996) 1992-2005
18. Schaefer E.J., and Asztalos B.F. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 17 (2006) 394-398
19. Asztalos B.F., Batista M., Horvath K.V., Cox C.E., Dallal G.E., Morse J.S., et al. Change in α-1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23 (2003) 847-852
20. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43 (2002) 1701-1707
21. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164 (2002) 361-369
22. Guerin M., Lassel T.S., Le Goff W., Farnier M., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
23. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
24. Guerin M., Bruckert E., Dolphin P.J., Turpin G., and Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 16 (1996) 763-772
25. Durrington P.N., Mackness M.I., Bhatnagar D., Julier K., Prais H., Arrol S., et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138 (1998) 217-225
26. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98 (2006) 361-369
27. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 111 (1994) 161-174
28. Turpin G., and Bruckert E. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Atherosclerosis 124 (1996) S83-S87
29. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., et al., DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737